Rosuvastatin Treatment is Associated with a Decrease of Serum Oxidised Low-Density Lipoprotein/Beta2-Glycoprotein I Complex Concentration in Type 2 Diabetes
Restricted accessResearch articleFirst published online November, 2010
Rosuvastatin Treatment is Associated with a Decrease of Serum Oxidised Low-Density Lipoprotein/Beta2-Glycoprotein I Complex Concentration in Type 2 Diabetes
To evaluate the effect of rosuvastatin on oxidised low-density lipoprotein/beta2-glycoprotein I (oxLDL/β2GPI) complex concentration in type 2 diabetes mellitus.
Methods
Open label 2:1 assignment of consecutive diabetic patients into oral rosuvastatin (10 mg daily for six weeks) arm or observational arm with measurements of serum oxLDL/|β2GPI complexes, nitric oxide metabolites, asymmetric dimethyl arginine, nitrotyrosine alongside routine biochemistry at baseline and end of study in all patients.
Results
After rosuvastatin treatment the mean serum concentration of oxLDL/β2GPI decreased from 0.79±0.49 units/mL to 0.53±0.36 units/mL (p<0.001). The decrease was statistically independent from the decrements of mean cholesterol, LDL and triglyceride concentrations (p<0.001) but probably dependent on the decrement of nitrate (p<0.001).
Conclusion
In type 2 diabetes, treatment with rosuvastatin was associated with a significant reduction of serum concentrations of oxLDL/β2GPI complexes, which is in further support of the already proposed effects of the drug on the oxidative metabolism of lipids and/or LDL. The oxLDL/β2GPI complex may represent a surrogate marker of oxidative stress in type 2 diabetes.
GiuglianoDCerielloAPaolissoG.Oxidative stress and diabetic vascular complications. Diabetes Care1996;19:257–67.
2.
ZadehNourooz JCooperMBZieglerDBetteridgeDJUrinary 8-epi-PGF2alpha and its endogenous beta-oxidation products (2, 3-dinor and 2, 3-dinor-5, 6-dihydro) as biomarkers of total body oxidative stress. Biochem Biophys Res Commun2005;330:731–6.
3.
GopaulNKAnggårdEEMalletAIPlasma 8-epi-PGF2 alpha levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Lett1995;368:225–9.
4.
DaviGCiabattoniGConsoliAIn vivo formation of 8-iso-prostaglandin F2 alpha and platelet activation in diabetes mellitus: Effects of improved metabolic control and vitamin E supplementation. Circulation1999;99:224–9.
5.
ThomasDDRidnourLAIsenbergJSThe chemical biology of nitric oxide: Implications in cellular signalling. Free Radic Biol Med2008;45:18–31.
6.
DenicolaABatthyanyCLissiEDiffusion of nitric oxide into low-density lipoprotein. J Biol Chem2002;277:932–6.
7.
PeluffoGRadiR.Biochemistry of protein tyrosine nitration in cardiovascular pathology. Cardiovasc Res2007;75:291–302.
8.
PacherPBeckmanJSLiaudetL.Nitric oxide and peroxynitrite in health and disease. Physiol Rev2007;87:315–24.
9.
CromwellWCBarringerTALow-density lipoprotein and apolipoprotein B: Clinical use in patients with coronary heart disease. Curr Cardiol Rep2009;11:468–75.
10.
MalleEMarscheGArnholdJDaviesMJModification of low-density lipoprotein by myeloperoxidase-derived oxidants and reagent hypo-chlorous acid. Biochim Biophys Acta2006;1761:392–415.
11.
LeeuwenburghCHardyMMHazenSLReactive nitrogen intermediates promote low-density lipoprotein oxidation in human atherosclerotic intima. J Biol Chem1997;272:1433–6.
12.
MatsuuraEShenLMatsunamiYPathophysiology of beta2-glycoprotein I in ntiphospholipid syndrome. Lupus2010;19:379–84.
13.
KobayashiKKishiMAtsumiTCirculating oxidized LDL forms complexes with β2-glycoprotein I: Implications as an atherogenic auto-antigen. J Lipid Res2003;44:716–26.
14.
AmesPRJAntinolfiICiampaAPrimary antiphospholipid syndrome: A low-grade auto-inflammatory disease? Rheumatology2008; 47:1832–7.
15.
LopezDValladaresGarcia ISanchezPalafox COxidized low-density lipoprotein/β2-glycoprotein I complexes and autoantibodies to oxLig-1/β2-glycoprotein I in patients with systemic lupus erythematosus and antiphospholipid syndrome. Am J Clin Pathol2004;121:426–36.
16.
KasaharaJKobayashiKMaeshimaYClinical significance of serum oxidized low-density lipoprotein/β2-glycoprotein I complexes in patients with chronic renal diseases. Nephron Clin Practice2004;98:15–24.
17.
LopezLRHurleyBLSimpsonDFMatsuuraE.Oxidized low-density lipoprotein/β2-glycoprotein I complexes in type 2 diabetes mellitus. Ann NY Acad Sci2005;1051:97–103.
18.
HertulaYla SPalinskiWRosenfeldMEEvidence for the presence of oxidatively modified low-density lipoprotein in atherosclerotic lesion of rabbit and man. J Clin Invest1989;84:1086–95.
19.
GeorgeJHaratsDGilburdBImmunolocalization of β2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: Potential implications for lesion progression. Circulation1999;99:2227–30.
20.
LiuQKobayashiKFurukawaJω-Carboxyl variants of 7-keto-cholesteryl esters are ligands for β2-glycoprotein I and mediate antibody-dependent uptake of oxidized LDL by macrophages. J Lipid Res2002;43:1486–95.
21.
MatsuuraEKobayashiKInoueKOxidized LDL/β2-glycoprotein I complexes: New aspects in atherosclerosis. Lupus2005;14:736–41.
22.
TabuchiMInoueKKataokaUsui HThe association of C-reactive protein with an oxidative metabolite of LDL and its implication in atherosclerosis. J Lipid Res2007;48:768–81.
23.
UndasAZiedinsBrummel KEMannKGStatins and blood coagulation. Arterioscler Thromb Vasc Biol2005;25:287–94.
24.
ShishehborMHBrennanMLAvilesRJStatins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation2003;108:426–31.
25.
World Health Organisation: Diabetes mellitus: Report of a WHO Study Group.Tech Rep Ser #727:1–113. Geneva: World Health Organisation, 1985.
26.
MontanoArellano SSosaBastarrachea RARodriguezBourges HLa obesidad en Mexico. Revista Endocrinologia Nutricion2004;12 (Suppl 3):S80–7.
27.
EckersonHWWyteCMLa DuBNThe human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet1983;35:1126–38.
28.
GiovannoniGLandJMKeirGAdaptation of the nitrate reductase and Griess reaction methods for the measurement of serum nitrate plus nitrite levels. Ann Clin Biochem1997;34:193–8.
29.
SongFJiaWYaoYOxidative stress, antioxidant status and DNA damage in patients with impaired glucose regulation and newly diagnosed Type 2 diabetes. Clin Sci (Lond)2007;112:599–606.
30.
SchneiderMPRittMRaffUOttC.Gender is related to alterations of renal endothelial function in type 2 diabetes. Nephrol Dial Transplant2009;24:3354–9.
31.
LiaoJKIsoprenoids as mediators of the biological effects of statins. J Clin Invest2002;110:285–8.
32.
EssigMNguyenGPrieD3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells: Role of geranylgeranylation and Rho proteins. Circ Res1998;83:683–90.
33.
EndresMLaufsUHuangZStroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A1998;95:8880–5.
34.
LaufsULa FataVPlutzkyJLiaoJKUpregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation1998;97:1129–35.
35.
BlakeGJRidkerPMAre statins anti-inflammatory? Curr Control Trials Cardiovasc Med2000;1:161–5.
36.
TakemotoMLiaoJKPleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol2001;21:1712–19.
37.
ReschUTatzberFBudinskyASinzingerH.Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy. Br J Clin Pharmacol2006;61:262–74.
38.
VerrethWDe KeyzerDDaveyPCRosuvastatin restores superoxide dismutase expression and inhibits accumulation of oxidized LDL in the aortic arch of obese dyslipidemic mice. Br J Pharmacol2007;151: 347–55.
39.
GrosserNErdmannKHemmerleARosuvastatin upregulates the antioxidant defense protein heme oxygenase-1. Biochem Biophys Res Commun2004;325:871–6.
40.
ManfrediniVBianciniGBVanzinCSApolipoprotein, C-reactive protein and oxidative stress parameters in dyslipidemic type 2 diabetic patients treated or not with simvastatin. Arch Med Res2010;41:104–09.
41.
SuYXuYSunYMComparison of the effects of simvastatin versus atorvastatin on oxidative stress in patients with type 2 diabetes mellitus. J Cardiovasc Pharmacol2010;55:21–5.
42.
AkalinATemizGAkcarNSensoyB.Short term effects of atorvastatin on endothelial functions and oxidized LDL levels in patients with type 2 diabetes. Endocr J2008;55:861–6.
43.
PaniaguaJAMirandaLopez JMartinezPerez POxidized-LDL levels are changed during short-term serum glucose variations and lowered with statin treatment in early Type 2 diabetes: A study of endothelial function and microalbuminuria. Diabet Med2005;22:1647–56.
